Home › Compare › TBIIF vs ABBV
TBIIF yields 1036.27% · ABBV yields 3.06%● Live data
📍 TBIIF pulled ahead of the other in Year 1
Combined, TBIIF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of TBIIF + ABBV for your $10,000?
Tobii AB (publ) develops and sells eye-tracking technology and solutions in Sweden, rest of Europe, the United States, Canada, Asia/Oceania, and internationally. It operates in two segments, Products & Solutions, and Integrations. The Products & solutions segments provides a suite of eye tracking hardware, which includes the Tobii Pro Glasses 3; research-grade and screen-based eye trackers, such as Pro Spectrum and Pro Fusion; and the Tobii Eye Tracker 5, a gaming eye tracker. This segment also includes software Tobii Pro Lab, Sticky, and the consultancy service Tobii Pro Insight. The Integration segment offers algorithms, software, hardware components, system reference designs, and IP-licenses to provide tailored solutions to address industry-specific problems. It serves the scientific studies and research, healthcare, assistive devices, education and training, gaming, extended reality, automotive, and other sectors. The company offers its products through resellers, agents, and distributors. Tobii AB (publ) was founded in 2001 and is headquartered in Danderyd, Sweden.
Full TBIIF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.